Advertisement · 728 × 90
#
Hashtag
#ATAINews
Advertisement · 728 × 90
Post image

Atai Life Sciences and Beckley Psytech have received FDA Breakthrough Therapy designation for their nasal spray BPL-003 (mebufotenin benzoate), targeting treatment-resistant depression in adults

#ATAI #ATAIStock #ATAINews #ATAIStockNews #ataiLifeSciences #ataiLifeSciencesLifeSciencesStock
$ATAI

0 0 0 0
Post image

Atai Life Sciences shares dropped over 15% in after-hours trading after its portfolio company Recognify Life Sciences reported that its schizophrenia drug inidascamine failed to meet the primary endpoint in a Phase 2b trial.

#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences
$ATAI

0 0 0 0
Post image

Atai Life Sciences shares rose after its psychedelic drug BPL-003, developed with Beckley Psytech, showed statistically significant reductions in depressive symptoms in a mid-stage trial for treatment-resistant depression (TRD).

#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences

0 0 0 0